Polymeric Stents and Method of Manufacturing Same

ABSTRACT

A pattern is used to form a stent scaffold from a polymeric precursor tube having a particular outer diameter. A new pattern can be derived from a base pattern, wherein the new pattern can be used to form a stent scaffold from a precursor tube having an outer diameter OD PR  smaller than that needed for the base pattern. The new pattern can be derived by determining the shape of a stent scaffold, having the base pattern, after having been radially compressed to OD PR . The radially compressed shape is used to design the new pattern, which is applied to a precursor tube having an outer diameter OD PR . The new pattern can have a plurality of W-shaped closed cells, each W-shape closed cell bounded by struts oriented in such a way to form interior angles from about 80 degrees to about 95 degrees between every two adjacent struts.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 13/758,741,filed Feb. 4, 2013, now U.S. Pat. No. 8,495,904, which is a divisionalof application Ser. No. 12/772,155, filed Apr. 30, 2010, now U.S. Pat.No. 8,370,120, both of which are incorporated herein by reference in itsentirety for all purposes.

FIELD OF THE INVENTION

This invention relates to expandable endoprostheses, and moreparticularly to methods of manufacturing polymeric stents.

BACKGROUND OF THE INVENTION

An “endoprosthesis” corresponds to an artificial device that is placedinside the body, more particularly, within an anatomical lumen. A“lumen” refers to a cavity of a tubular organ such as a blood vessel. Astent is an example of an endoprosthesis. Stents are generallycylindrically shaped devices, which function to hold open and sometimesexpand a segment of a blood vessel or other anatomical lumen such asurinary tracts and bile ducts. Stents are often used in the treatment ofatherosclerotic stenosis in blood vessels.

The treatment of a diseased site or lesion with a stent involves bothdelivery and deployment of the stent. “Delivery” refers to introducingand transporting the stent through an anatomical lumen to a region, suchas a lesion, in a vessel that requires treatment. “Deployment”corresponds to the expanding of the stent within the lumen at thetreatment region. Delivery and deployment of a stent are accomplished bypositioning the stent about one end of a catheter, inserting the end ofthe catheter through the skin into an anatomical lumen, advancing thecatheter in the anatomical lumen to a desired treatment location,expanding the stent at the treatment location, and removing the catheterfrom the lumen.

In the case of a balloon expandable stent, the stent is mounted about aballoon disposed on the catheter. Mounting the stent typically involvesradially compressing or crimping the stent onto the balloon. The stentis then expanded by inflating the balloon. The balloon may then bedeflated and the catheter withdrawn.

The stent must be able to satisfy a number of mechanical requirements.First, the stent must be capable of withstanding the structural loads,namely radial compressive forces, imposed on the stent as it supportsthe walls of an anatomical lumen. Therefore, a stent must possessadequate radial strength. Radial strength, which is the ability of astent to resist radial compressive forces, is due to strength andrigidity around a circumferential direction of the stent. Radialstrength and rigidity, therefore, may also be described as hoop strengthand rigidity.

Once expanded, the stent must adequately maintain its size and shapethroughout its service life despite the various forces that may come tobear on it, including the cyclic loading induced by the beating heart.For example, a radially directed force after deployment may cause astent to plastically deform, which can reduce clinical effectiveness.

In addition, the stent must possess sufficient flexibility to allow forcrimping, deployment, and cyclic loading after deployment. Longitudinalflexibility is important to allow the stent to be maneuvered through atortuous anatomical path and to enable it to conform to a deploymentsite that may not be linear or may be subject to flexure. Also, thestent must be biocompatible so as not to trigger any adverse responses.

The structure of a stent typically comprises scaffolding that includes apattern or network of interconnecting structural elements often referredto in the art as struts, links and rings. The scaffolding is designed sothat the stent can be radially compressed (to allow crimping) andradially expanded (to allow deployment).

Polymers have been used to make stent scaffolding. The art recognizes avariety of factors that affect a polymeric stent's ability to retain itsstructural integrity when subjected to external loadings, such ascrimping and balloon expansion forces. These interactions are complexand the mechanisms of action not fully understood. According to the art,characteristics differentiating a polymeric, bio-absorbable stentscaffolding of the type expanded to a deployed state by plasticdeformation from a similarly functioning metal stent are many andsignificant. Indeed, several of the accepted analytic or empiricalmethods/models used to predict the behavior of metallic stents tend tobe unreliable, if not inappropriate, as methods/models for reliably andconsistently predicting the highly non-linear behavior of a polymericload-bearing, or scaffolding portion of a balloon-expandable stent. Themodels are not generally capable of providing an acceptable degree ofcertainty required for purposes of implanting the stent within a body,or predicting/anticipating the empirical data.

Polymer material considered for use as a polymeric stent scaffolding,such as PLLA and PLGA, may be described through comparison with ametallic material conventionally used to form stent scaffolding. Incomparison to metals, a suitable polymer has a low strength to weightratio, which means more material is needed to provide an equivalentmechanical property to that of a metal. Therefore, struts in polymericscaffolding must be made thicker and wider to have the strength needed.Polymeric scaffolding also tends to be brittle or have limited fracturetoughness. The anisotropic and rate-dependant inelastic properties(i.e., strength/stiffness of the material varies depending upon the rateat which the material is deformed) that are inherent in the materialonly compound this complexity in working with a polymer, particularly, abio-absorbable polymer such as PLLA and PLGA.

Therefore, processing steps performed on and design changes made to ametal stent that have not typically raised concerns for unanticipatedchanges in the average mechanical properties, may not also apply to apolymer stent due to the non-linear and sometimes unpredictable natureof the mechanical properties of the polymer under a similar loadingcondition. It is sometimes the case that one needs to undertakeextensive validation before it even becomes possible to predict moregenerally whether a particular condition is due to one factor oranother—e.g., was a defect the result of one or more steps of afabrication process, or one or more steps in a process that takes placeafter stent fabrication, e.g., crimping. As a consequence, a change to afabrication process, post-fabrication process or even relatively minorchanges to a stent pattern design must, generally speaking, beinvestigated more thoroughly than if a metallic material were usedinstead of the polymer. It follows, therefore, that when choosing amongdifferent polymeric stent designs for improvement thereof, there are farless inferences, theories, or systematic methods of discovery available,as a tool for steering one clear of unproductive paths, and towards moreproductive paths for improvement, than when making design changes in ametal stent.

It is recognized, therefore, that, whereas inferences previouslyaccepted in the art for stent validation or feasibility when anisotropic and ductile metallic material was used, such inferences wouldbe inappropriate for a polymeric stent. A change in a polymeric stentpattern may affect, not only the stiffness or lumen coverage of thestent in its deployed state, but also the propensity for fractures todevelop when the stent is crimped or being deployed. This means that, incomparison to a metallic stent, there is generally no assumption thatcan be made as to whether a changed stent pattern may not produce anadverse outcome, or require a significant change in a processing step(e.g., tube forming, laser cutting, crimping, etc.). Simply put, thehighly favorable, inherent properties of a metal (generally invariantstress/strain properties with respect to the rate of deformation or thedirection of loading, and the material's ductile nature), which simplifythe stent fabrication process, allow for inferences to be more easilydrawn between a changed stent pattern and/or a processing step and theability for the metallic stent to be reliably manufactured with the newpattern and without defects when implanted within a living being.

A change in the pattern of the struts and rings of a polymeric stentscaffolding that is plastically deformed, both when crimped to, and whenlater deployed by a balloon, unfortunately, is not as easy to predict asa metal stent. Indeed, it is recognized that unexpected problems mayarise in polymer stent fabrication steps as a result of a changedpattern that would not have necessitated any changes if the pattern wasinstead formed from a metal tube. In contrast to changes in a metallicstent pattern, a change in polymer stent pattern may necessitate othermodifications in fabrication steps or post-fabrication processing, suchas crimping and sterilization.

A problem encountered with polymeric stents after they are crimped ontoa balloon is the development of fractures and other defects that requirethe stent to be rejected and scrapped. Cracks and other defects canrender the stent incapable of functioning properly when fully deployedby the balloon. Another problem is that deployment of polymeric stentsfrom the crimped state to a deployed state in a patient can producestrain that adversely affects the ability of the stent to stay in thedeployed state and remain at the implantation site, especially undercyclic loading conditions inherent in a patient's circulatory system.The strain induced during deployment can result in significant loss inradial strength.

In light of the foregoing, there is a need for a stent pattern andmanufacturing method that reduces the cracks and other defects due tocrimping. There is also a need for a stent pattern and manufacturingmethod that results in less strain when a stent is deployed forimplantation.

SUMMARY OF THE INVENTION

Briefly and in general terms, the present invention is directed to astent and a method of manufacturing a stent.

In aspects of the present invention, a method comprises determining ashape of a first stent scaffold radially compressed to a reduced outerdiameter, the stent scaffold capable of being deployed to an expandedouter diameter. The method further comprises determining a pattern fromthe determined shape, and forming a second stent scaffold by applyingthe determined pattern to a precursor tube having the reduced outerdiameter. The second stent scaffold is capable of being deployed to theexpanded outer diameter.

In other aspects of the present invention, a method comprises providinga precursor tube made of PLLA, and forming a stent scaffold by applyinga pattern of struts on the precursor tube. The pattern comprises aplurality of W-shaped closed cells, each W-shape closed cell bounded bystruts that are substantially linear, the struts oriented in such a wayto form interior angles from about 80 degrees to about 95 degreesbetween every two adjacent struts.

In other aspects of the present invention, a stent comprises a stentscaffold made of PLLA. The stent scaffold comprises a plurality ofstruts forming a plurality of rings, each pair of adjacent ringsconnected to each other by links that are substantially linear. There isexactly three W-shaped closed cells enclosed within each pair ofadjacent rings. The struts are substantially linear and oriented in sucha way to form interior angles from about 80 degrees to about 95 degreesbetween every two adjacent struts.

The features and advantages of the invention will be more readilyunderstood from the following detailed description which should be readin conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flow chart showing a process for manufacturing a polymericstent scaffold from a precursor tube followed by deployment of the stentscaffold.

FIG. 2 is a perspective view of a precursor tube.

FIG. 3 is a perspective view of a stent scaffold.

FIG. 4 is flow chart showing the relative outer diameter sizes duringthe process of manufacturing the stent scaffold according to FIG. 1.

FIG. 5 is a plan view of a pattern of struts to be applied to aprecursor tube to form a stent scaffold.

FIG. 6 is a detailed view of a portion of the pattern of FIG. 5.

FIG. 7A-7C are plan views of different patterns derived from the basepattern of FIG. 5, the derived patterns to be used to form stentscaffolds from precursor tubes having a reduced outer diameter for thepurpose of reducing the incidence of defects during crimping.

FIG. 8 is a flow chart showing a process for deriving a new pattern froma base pattern by predicting the shape of a stent scaffold that has beenradially compressed to a reduced diameter, the derived pattern to beused to form a stent scaffold from a precursor tube having the reduceddiameter for the purpose of reducing the incidence of fractures duringcrimping.

FIG. 9 is a plan view of a new pattern derived from the base pattern ofFIG. 5 according to the method described in connection with FIG. 8.

FIG. 10 is a graph showing the number of stent scaffolds rejected due tofracture during crimping, and showing a reduction in the number ofrejects for stent scaffolds of the new pattern of FIG. 9 as compared tothe base pattern of FIG. 5.

FIGS. 11A and 1 lB are flow charts showing a process of manufacturingstent scaffolds using the base pattern of FIG. 5 and the new pattern ofFIG. 9, respectively.

FIGS. 12A-12C are isometric views of finite element models of stentscaffolds using: (A) a new pattern applied to a precursor tube having a2.5 mm outer diameter, (B) the new pattern of FIG. 9 applied to aprecursor tube having a 3.0 mm outer diameter, and (B) the base patternof FIG. 5 applied to a precursor tube having a 3.5 mm outer diameter.

FIGS. 13A-13C are isometric views of the finite element models of FIGS.12A-12C after simulating deployment to an outer diameter of 3.5 mm.

FIGS. 14A-14C are views of sequential steps for a process for deriving anew pattern from a base pattern by tracking changes in position ofcontrol points during simulation of radial compression of a stentscaffold.

FIG. 15 is a flow chart showing an analytical process for deriving a newpattern from a base pattern by numerically simulating radial compressionfor an original stent scaffold which is then used to form a new patternfor making a new stent scaffold.

FIG. 16 is a flow chart showing an empirical process for deriving a newpattern from a base pattern by radially compressing a first stentscaffold which is then used to form a new pattern for making a secondstent scaffold.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, “biocompatible” refers to a polymer that both in itsintact, as synthesized state and in its decomposed state, i.e., itsdegradation products, is not, or at least is minimally, toxic to livingtissue; does not, or at least minimally and reparably, injure(s) livingtissue; and/or does not, or at least minimally and/or controllably,cause(s) an immunological reaction in living tissue.

As used herein, the terms “bioabsorbable,” “biodegradable,” and“absorbed,” are used interchangeably (unless the context showsotherwise) and refer to materials that are capable of being degraded orabsorbed when exposed to bodily fluids such as blood, and componentsthereof such as enzymes, and that can be gradually resorbed, absorbed,and/or eliminated by the body.

The words “substantially” or “substantial” as used herein to modify acondition means that the condition is present in absolute or perfectform, as well as in a form that is not necessarily absolute or perfectbut would be considered close enough to those of ordinary skill in theart to warrant designating the condition as still being present.

FIG. 1 depicts a method for making and deploying a stent. The methodincludes providing 10 a precursor tube of solidified polymer material,removing 12 material from the precursor tube to form a stent scaffold,crimping 14 the stent scaffold onto a balloon, then expanding 16 thestent scaffold to a deployed state. Expansion 16 of the stent scaffoldis performed by inflating the balloon after the stent scaffold has beenpositioned at the desired position within the patient.

An exemplary precursor tube is shown in FIG. 2. The precursor tube 20has a central axis 22, an inner diameter ID_(P), and an outer diameterOD_(P). The precursor tube 20 is made of a biocompatible polymerintended to form the core material or substrate of the stent scaffold.The phrase “substrate” refers to the material at the core of thestructural element of the stent scaffold and does not include anycoatings of other material deposited after formation of the stentscaffold. A segment of a conventional stent scaffold 24 is shown in FIG.3. The stent scaffold 24 includes a plurality of struts 26 which form aplurality of ring structures 27 connected to each other by links 28. Thering structures are configured to collapse during crimping and expandduring deployment. The central axis 22 of the stent scaffold correspondsto that of the precursor tube 20.

As used herein “substrate polymer” refers to the polymer used to makethe precursor tube 20. The substrate polymer can be bioabsorbable.Bioabsorbable polymers include without limitationpoly(lactic-co-glycolic acid) (PLGA) and poly (L-lactic acid) (PLLA).PLLA is a monomer and PLGA is a co-polymer in which the percentage ofglycolic acid (GA) may vary. PLLA and PLGA are semi-crystalline polymersin that their morphology includes crystalline and amorphous regions,though the amount of crystallinity can be altered to provide the desiredcombination of mechanical properties of the stent scaffold, such asflexibility to allow for crimping, toughness or resistance to fractureduring crimping and deployment, and rigidity to support surroundinganatomical tissue after deployment. Other suitable polymers includewithout limitation poly(L-lactide-co-D-lactide) (“PLLA-co-PDLA”),poly(L-lactic acid)/poly(D-lactic acid) (“PLLA/PDLA”) stereocomplex, andPLLA-based polyester block copolymer containing a rigid segment and asoft segment, the rigid segment being PLLA or PLGA, the soft segmentbeing poly(ε-caprolactone) (“PCL”) or poly(trimethylene carbonate)(“PTMC”). Other suitable substrate polymers and particular compositionsfor PLLA and PLGA include those described in commonly assigned U.S.patent application Ser. No. 12/558,105, entitled, “Polymeric Stent andMethod of Making Same”, filed Sep. 11, 2009, which is incorporatedherein by reference.

The precursor tube 20 is made by an extrusion process 30 and blowmolding process 32 (FIG. 1). In the extrusion process 30, the substratepolymer is fed into an extruder. In the extruder the substrate polymeris melted at a controlled temperature and a controlled pressure, thenforced through an annular die to form an extruded tube. The extrusionprocess 30 can be as described in U.S. Pub. No. 20060020330, which isincorporated herein by reference.

Presently, preferred dimensions for the extruded tube, when solidified,are as follows. A PLLA extruded tube having 0.025 inch ID and 0.066 inchOD is radially expanded to make a 3.5 mm precursor tube. A PLLA extrudedtube having 0.021 inch ID and 0.064 inch OD is radially expanded to make3.0 mm OD precursor tube. A PLLA extruded having 0.17 inch ID and 0.054inch OD is radially expanded to make a 2.5 mm OD precursor tube. Theabbreviation “ID” refers to the inner diameter of the tube, and theabbreviation “OD” refers to outer diameter of the tube.

The blow molding process 32 is performed on the extruded tube to form aprecursor tube with a desired combination of dimensions and mechanicalproperties. The blow molding process 32 induces orientation in molecularpolymer chains. The blow molding process 32 comprises placing theextruded tube into a glass tubular mold in which the extruded tube isheated to a controlled temperature. A gas is pumped into the extrudedtube to achieve a controlled internal pressure which causes the extrudedtube to radially expand within the tubular mold. Radial expansion occursat a segment of the extruded tube where heat is concentrated by a nozzleblowing heated gas onto an outer surface of the tubular mold. Becausethe heating device travels along the axial length of the extruded tubeat a controlled rate of travel, radial expansion occurs in a progressivefashion, starting from one end of the extruded tube and progressingtoward the opposite end of the extruded tube, such as described in U.S.Publication Nos. 20090001633 and 20090146348, which are incorporatedherein by reference. The process parameters, such as heatingtemperature, pressure, rate of travel of the heating device, can be asdescribed in U.S. patent application Ser. No. 12/558,105, entitled,“Polymeric Stent and Method of Making Same”, filed Sep. 11, 2009, whichis incorporated herein by reference, and in U.S. Pub. No. 20090146348.These process parameters and other processing conditions can also be asdescribed in U.S. Pub. No. 20100025894, which is incorporated herein byreference. Upon completion of radial expansion, the resulting tube iscooled or allowed to cool, then removed from the tubular mold for use asthe precursor tube 20.

The tubular mold has a predetermined inner diameter which corresponds tothe desired outer diameter OD_(P) of the precursor tube 20 and the outerdiameter of the stent scaffold which is made from the precursor tube.The desired outer diameter of the precursor tube is carefully selectedbecause it directly determines the amount of radial expansion as well asthe amount and direction of molecular polymer chain orientation thatwill be induced during the blow molding process 32, which in turn affectthe mechanical properties of the stent scaffold.

There are several interrelated and competing considerations for choosingthe outer diameter OD_(P) of the precursor tube 20. As previouslyindicated, OD_(P) also corresponds to the outer diameter of the stentscaffold immediately after its formation by removal 12 of material fromthe precursor tube 20.

One consideration for choosing the outer diameter OD_(P) of theprecursor tube is the hoop strength of the stent scaffold. Hoop strengthenables the stent scaffold to withstand radial compressive forces fromthe surrounding anatomical lumen after deployment within a patient. Hoopstrength could be increased by choosing OD_(P) that is substantiallylarger than the outer diameter OD_(E) of the extruded tube at the startof blow molding process. If OD_(P) is small and close in size to OD_(E),the molecular polymer chain orientation in the circumferential directionthat is induced during the blow molding process may be insufficient toprevent the stent scaffold from partially collapsing radially inward(referred to as “recoil”) or from totally collapsing after deployment.Hoop strength could also be increased by choosing OD_(P) that is closeto the intended deployed diameter OD_(DEPLOY) of the stent scaffold. IfOD_(P) is too small in relation to OD_(DEPLOY), shape memory, due toplastic deformation or despite plastic deformation during deployment,may be such that the stent scaffold recoils inward or contracts slightlyimmediately or soon after deployment. Also, an overly small OD_(P) inrelation to OD_(DEPLOY) may result in fracture due to strain caused byballoon expansion that forces the stent scaffold to the deployeddiameter OD_(DEPLOY). Post-deployment recoil or fractures could resultin loss of patency of the anatomical lumen being treated.

Another consideration for choosing the outer diameter OD_(P) of theprecursor tube is flexibility to allow the stent scaffold to be crimpedto the desired crimp diameter OD_(CRIMP). Flexibility is also needed toenable movement and positioning of the stent scaffold within tortuousand tight spaces within the anatomy prior to deployment. Flexibility canbe enhanced by choosing OD_(P) that is close to the outer diameterOD_(E) of the extruded tube at the start of blow molding process. If theOD_(P) is too large in relation to the OD_(E), the molecular polymerchain orientation in the circumferential direction that is inducedduring the blow molding process may make the stent scaffold too stiff orrigid, resulting in fractures. The ability of the stent scaffold to becrimped can be enhanced by choosing OD_(P) that is close to the desiredcrimp diameter as OD_(CRIMP). An overly large OD_(P) in relation toOD_(CRIMP) would cause more flexure of the stent scaffold duringcrimping, which corresponds to more strain during crimping that cancompromise structural integrity. Also, if the OD_(P) is too large inrelation to OD_(CRIMP), elastic shape memory, due to plastic deformationor despite plastic deformation during crimping, may be such that thestent scaffold springs outward or expands slightly immediately or soonafter crimping. Post-crimping expansion and fractures can compromiseretention of the stent scaffold on the delivery balloon and cancompromise the functional life of the stent scaffold. Thus, it should beunderstood that considerations for selecting of OD_(P) of the precursortube are varied and complex.

A preferred size relationship of the above described outer diameters isshown in FIG. 4 which is not drawn to scale. The outer diameter OD_(E)of the extruded tube is the smaller than the outer diameter OD_(P) ofthe precursor tube. The deployed diameter OD_(DEPLOY) of the stentscaffold is greater than the initial diameter OD_(P) of the stentscaffold. The crimped diameter OD_(CRIMP) of the stent scaffold is lessthan OD_(E). In other embodiments, OD_(P) and OD_(DEPLOY) are thesubstantially the same.

Yet another consideration for choosing the outer diameter OD_(P) of theprecursor tube is the geometric pattern applied to the precursor tube tomake the stent scaffold. The pattern must be able to collapse fromOD_(P) to the requisite crimp diameter OD_(CRIMP) and expand toOD_(DEPLOY), as shown in FIG. 4.

FIG. 5 shows an example of a geometric pattern 40 applied to a precursortube to make a stent scaffold. The pattern 40 is designed to collapsefrom OD_(P)=3.5 mm to crimp diameter OD_(CRIMP)=1.3 mm and expand toOD_(DEPLOY)=3.8 mm (ID_(DEPLOY)=3.5 mm). As used herein, the “=” symbolmeans “substantially equal to.” The pattern 40 is the same as thepattern described in connection with FIGS. 4-9 of U.S. Pub. No.20080275537, which is incorporated herein by reference. FIG. 6 shows adetail view of a portion of FIG. 5. The pattern 40 is of interconnectedstructural elements which form a regularly repeating arrangement ofW-shaped closed cells 42 that are offset from each other in brickdesign. The structural elements include substantially linear struts 44,bending elements 46, and substantially linear links 48.

The pattern of FIG. 5 is shown in a planar or flat state, although thepattern is actually in tubular form when cut onto the precursor tube.The bottom edge of the pattern in FIG. 5 actually meets with and isconnected to the top edge of the pattern so as to form the tubular bodyof the stent scaffold. Thus, it will be appreciated that the linearstruts, when formed on the precursor tube 20, form a plurality ofserpentine rings 50 that encircle the central axis of the stentscaffold. The rings 50 are connected to each other by the links 48 whichare substantially parallel to the central axis of the stent scaffold.The struts 44 are interconnected end-to-end by the bending elements 46to form the rings 50. The rings 50 are arranged axially to form thetubular body of the stent scaffold. The struts 44 are configured to havesufficient rigidity that provides the rings 50 with the hoop strengthneeded after deployment. The bending elements 46 are configured to havesufficient flexibility to provide the rings 50 with the ability to becrimped and deployed without sustaining significant structural damage.The links 48 are configured to have sufficient flexibility that providesthe stent scaffold with the ability to bend and pass through tortuouspassageways within the anatomy prior to deployment. It should also beunderstood that the choice of material for the stent scaffold substratealso affects hoop strength and flexibility.

The geometric pattern 40 can be applied to the precursor tube 20 byinputting the pattern into a CAD/CAM software program that generates alaser cut routine which is then used to cut and remove material from theprecursor tube 20. The pattern 40 can be cut onto the precursor tube 20by a laser cutting process, such as described in U.S. Pub. Nos.20070034615 and 20070151961, both of which are incorporated herein byreference.

The selected outer diameter OD_(P) of the precursor tube 20 affects theamount of radial expansion from OD_(E), which in turn affect themechanical properties of the individual struts, bending elements, andlinks of the resulting stent scaffold. The mechanical properties ofthese individual structural elements are also affected by theorientation of the individual structural elements. Due to radialexpansion and the resulting molecular orientation of polymer chainsinduced during the blow molding process, structural elements areexpected to be stiffer in the circumferential direction (vertical arrow41 in FIG. 5) than in the axial orientation (horizontal arrow 43 in FIG.5). In combination with orientation of the individual structuralelements, stiffness and flexibility among the structural elements willdepend upon the amount of radial expansion that occurs during the blowmolding process 32, which depends directly on the chosen outer diameterOD_(P) of the precursor tube.

Referring again to FIG. 5, the pattern 40 is to be applied to theprecursor tube 20 for making a stent scaffold. The pattern has acircumferential dimension, from the bottom edge to the top edge, ofabout 11 mm and more narrowly 10.89 mm, which corresponds to thecircumference of the outer diameter OD_(P)=3.5 mm of the precursor tube.The pattern 40, details of which are discussed further below, isdesigned to allow the stent scaffold to be crimped to an outer diameterOD_(CRIMP) of about 1.3 mm and radially expanded to at least an innerdiameter ID_(DEPLOY) of about 3.5 mm and outer diameter OD_(DEPLOY) ofabout 3.8 mm.

As previously discussed, a problem with polymeric stents is that theycan fracture during crimping and deployment. Non-uniform collapse ofstruts during crimping can also be a problem. In the case of the patternof FIG. 5 as applied to a precursor tube having OD_(P)=3.5 mm, thefractures and/or non-uniform collapse that develop are of sufficientnumber and/or are located at particular regions of the stent scaffold towarrant rejection of 24% to 30% of stent scaffolds manufactured. One wayto reduce the incidence of fractures during crimping might be to cut thepattern onto a precursor tube having a reduced outer diameter that issmaller than OD_(P) and closer in size to OD_(CRIMP). Having a reducedouter diameter, denoted OD_(PR), that is closer to OD_(CRIMP) willreduce the amount of flexure and deformation that the stent scaffoldmust undergo during the crimping process 14 to achieve OD_(CRIMP).However, as discussed above, reducing the outer diameter of theprecursor tube will increase the amount of flexure and deformation thatthe stent scaffold must undergo during the deployment process 16 toachieve OD_(DEPLOY). Also, reducing the outer diameter of the precursortube, without also reducing the outer diameter OD_(E) of the extrudedtube, will decrease the amount of radial expansion of the extruded tubethat occurs during the blow molding process to make the precursor tube,and such reduction affects the amount and direction of molecular polymerchain orientation induced, which in turn affects mechanical propertiesof the resulting stent scaffold.

The pattern of FIG. 5 is too large in the circumferential direction tofit on a precursor tube with a reduced outer diameter OD_(PR), so thepattern must first be modified. As previously indicated, the pattern 40has a circumferential dimension, from the bottom edge to the top edge,of about 11.0 mm which corresponds to OD_(P)=3.5 mm. A precursor tubewith a reduced outer diameter OD_(PR)=3.0 mm will have an outercircumference of about 9.4 mm. Thus, the pattern 40 is about 1.6 mm toolarge in the circumferential direction to be applied to a precursor tubewith OD_(PR)=3.0 mm.

Various approaches can be taken to adjust the pattern 40 of FIG. 5 forapplication with a precursor tube having reduced outer diameterOD_(PR)=3.0 mm. One approach is to cut 1.6 mm from the pattern, as shownin FIG. 7A, to produce a pattern 50 with a 9.4 mm circumferentialdimension that matches a precursor tube with OD_(PR)=3.0 mm. A problemwith this approach is that the structural elements at the bottom edge ofthe resulting pattern 50 in FIG. 7A will not meet with those at the topedge. Also, removal of some of the stent struts 44 (in the boxillustrated in broken line) means that there will be fewer remainingstruts to support the surrounding anatomical lumen after deployment in apatient. Removal of some of the struts 44 will also prevent the stentscaffold from being deployed to the same extent as the base pattern 40of FIG. 5.

Another approach for adjusting the pattern 40 of FIG. 5 for applicationwith a precursor tube having OD_(PR) less than 3.5 mm is to scale downthe pattern 40 so that it has a circumferential dimension thatcorresponds with the reduced diameter. For example, the pattern 40 canbe scaled down, as shown in FIG. 7B, to produce a pattern 50′ with a 9.4mm circumferential dimension that matches a precursor tube withOD_(PR)=3.0 mm. A problem with this approach is that the width of thestructural elements will also be scaled down, which can make the struts44 insufficiently rigid and make the bending elements 46 and links 48overly flexible. Also, the total length of the stent will be reduced.Another shortcoming is that the length of the struts 44 and links 48will also be scaled down, which can prevent the stent scaffold frombeing deployed to the same extent as the base pattern 40 of FIG. 5.

Yet another approach for adjusting the base pattern 40 of FIG. 5 forapplication with a precursor tube having OD_(PR) less than 3.5 mm is toscale down the pattern 40 in the circumferential direction, as shown inFIG. 7C, without scaling down the pattern in the axial direction. Aproblem with this approach is that length of the struts 44 in the newpattern 50″ will also be scaled down (although to a lesser extent thanin FIG. 7B), which can prevent the stent scaffold from being deployed tothe same extent as the base pattern 40 of FIG. 5.

Applicant has found that a better approach for adjusting the basepattern 40 of FIG. 5 for application with a precursor tube havingOD_(PR) less than 3.5 mm is to use a method, as shown in FIG. 8, topredict the shape of the stent scaffold at OD_(PR) and then use thepredicted shape to design a new pattern that is applied to a precursortube with an outer diameter of OD_(PR). The pattern 40 of FIG. 5 isreferred to as a base pattern from which the new pattern is to bederived. The prediction step comprises constructing 60 athree-dimensional computer or numerical model of the stent scaffold madewith the base pattern 40 of FIG. 5 applied to a precursor tube withOD_(P)=3.5 mm. The model is referred to as a finite element modelbecause it comprises a plurality of discrete elements or blocks arrangedin the shape of the actual stent scaffold. Finite element modelingmethods are known in the art, so details need not be described in detailherein. Generally, the model includes mathematical equations thatcharacterize how the discrete elements can deform and/or move relativeto each other. A plurality of control points on the model are selectedfor tracking purposes. Next, the model is used to simulate 62 crimpingof the stent scaffold to a reduced outer diameter OD_(PR). The changedposition of the control points are exported 64, then used 66 to design anew pattern that can be applied onto a precursor tube of reduced outerdiameter OD_(PR). In this way, the new pattern matches the controlpoints for the precursor tube of OD_(PR). The new pattern is inputted toa CAD/CAM software to generate a laser cut routine that is applied tothe precursor tube of OD_(PR).

FIG. 9 shows a new pattern 700 for use with a precursor tube havingOD_(PR)=3.0 mm. The new pattern 700 was derived according to the methodof FIG. 8 from the base pattern 40 of FIG. 5 for OD_(P)=3.5 mm. Like thenew patterns 50, 50′, 50″ of FIGS. 7A-7C, the new pattern 700 of FIG. 9has a circumferential dimension of 9.4 mm. However, unlike the newpatterns of FIGS. 7A-7C, the new pattern 700 is capable of expanding tothe same extent as the base pattern 40 of FIG. 5 since no struts wereremoved and since the length of the struts are substantially unchanged.Over a hundred PLLA stent scaffolds were made with the new pattern 700cut onto a precursor tube with OD_(PR)=3.0 mm. Each scaffold had outerdiameter of 3.0 mm. The stent scaffolds were then crimped and inspectedfor fractures and other crimp defects, such as non-uniform collapse ofstruts. Applicant found that, when using the same standard of inspectionapplied to the base pattern 40 of FIG. 5 applied to PLLA OD_(P)=3.5 mm,the new pattern 700 of FIG. 9 applied to PLLA OD_(PR)=3.0 mm yielded 0%rejections. This is a significant reduction in rejects, as shown in FIG.10.

As indicated above, a reduction in the outer diameter of the precursortube can be expected to increase the amount of strain experienced by thebending elements of the stent scaffold during deployment because of theneed for increased flexure. The need for increased flexure isillustrated in FIGS. 11A and 11B, which are not drawn to scale. FIG. 11Ashows the process for the base pattern 40 of FIG. 5 applied toOD_(P)=3.5 mm, and FIG. 11B shows the process for the new pattern 700 ofFIG. 9 applied to OD_(PR)=3.0 mm. Comparison of FIGS. 11A and 11Bindicates that the bending elements of the stent scaffold made with thenew pattern 700 will have to flex beyond its original diameter ofOD_(PR) to reach the deployment diameter OD_(DEPLOY) of 3.8 mm, whichsuggests that strain experienced by the stent scaffold should increasewith the new pattern 700. However, Applicant has unexpectedly found thatstrain decreases with the new pattern.

FIGS. 12A-12C show finite element models of respective axial segments ofthe stent scaffolds made from a new pattern applied to OD_(PR)=2.5 mm(FIG. 12A), the new pattern 700 of FIG. 9 applied to OD_(PR)=3.0 mm(FIG. 12B), and the base pattern 40 of FIG. 5 applied to OD_(P)=3.5 mm(FIG. 12C). The new patterns for OD_(PR) of 2.5 mm and 3.0 mm aredifferent from each other, and were separately derived from the basepattern 40 according to the method described in connection with FIG. 8.FIGS. 13A-13C show the same finite element models simulating deploymentto ID_(DEPLOY)=3.5 mm, which corresponds to OD_(DEPLOY) of about 3.8 mm.The simulations show the location of greatest strain in the stentscaffold to be at the bending elements.

TABLE 1 and FIGS. 13A-13C show the maximum strain at OD_(DEPLOY)˜3.8 mm,as a percentage of the strain that will result in fracture. For the basepattern of FIG. 3 applied to OD_(P)=3.5 mm, the maximum strain atOD_(DEPLOY)˜3.8 mm is 89%. The maximum strain is lower for the newpatterns (derived from the base pattern according to the method of FIG.8) applied to precursor tubes having reduced outer diameters OD_(PR) of3.0 mm and 2.5 mm. This decrease is unexpected. As previously explainedin connection with FIGS. 11A and 11B, it was expected that strain atdeployment would be higher with the smaller precursor tubes because thesmaller precursor tubes would have to expand beyond their originaldiameter to reach the deployment diameter.

TABLE 1 Precursor Tube Outer Maximum Strain at Deployment, DiameterOD_(DEPLOY)~3.8 mm 3.5 mm 89% (see FIG. 13C) 3.0 mm 86% (see FIG. 13B)2.5 mm 78% (see FIG. 13A)

In addition to the method of FIG. 8, other methods are contemplated forderiving a new pattern for use on a precursor tube with a reduced outerdiameter. Those methods are described below in connection with FIGS.14-16.

In one exemplary method, as shown in FIG. 14A-14C, a new pattern isderived by constructing a numerical or computerized model 80 of at leasta portion of a stent scaffold having an outer diameter OD_(P) and havinga base pattern of struts 82, bending elements 84, and links 86. Bytaking into account mechanical properties and dimensions of thesubstrate, the model 80 is designed to allow simulation of radialcompression of the actual stent scaffold, such as would occur duringcrimping. Certain points on the model are designated as control points81. The control points can correspond to regions of the model which areexpected to bend. The control points can correspond to intersectionpoints on the model 80 where the struts 82, bending elements 84, andlinks 86 meet. The control points 81 are illustrated as X's in FIG. 14A.The control points 81 are located at the edges of the model 80. It willbe appreciated that the control points 81 can be located elsewhere onthe model 80.

Referring to FIG. 14B, a simulation of radial compression of the stentscaffold is performed on the model 80. The simulation comprisesselecting a reduced outer diameter OD_(PR) to which the model 80 will beradially compress. The simulation causes movement of the model's struts82, bending elements 84, and links 86. As a result, the control points81 move to new positions. In FIG. 14B, the original positions of thecontrol points 81 (prior to simulation of radial compression) areillustrated with solid-line X's and the new positions of the controlpoints (after simulation of radial compression) are illustrated withbroken-line X's. The model 80 is not illustrated in FIG. 14B to clearlyshow the change in positions.

Referring to FIG. 14C, the new positions of the control points 81 areused to construct a new pattern 90 which corresponds to the predictedshape of the stent scaffold upon radial compression to the reduced outerdiameter OD_(PR).

The above analytical process for deriving the new pattern 90 from thebase pattern is further illustrated in FIG. 15. It is to be understoodthat the base pattern and OD_(P) are such that the original stentscaffold is capable of deploying to an outer diameter OD_(DEPLOY). A newstent scaffold is formed by applying the new pattern 90 on a precursortube having the reduced outer diameter OD_(PR). The stent scaffold canthen be crimped to OD_(CRIMP) onto a delivery balloon and subsequentlydeployed to OD_(DEPLOY) by inflating the balloon. In FIG. 15, OD_(P) andOD_(DEPLOY) are not substantially the same. It will be appreciated that,depending on the anatomical lumen being treated, OD_(DEPLOY) can besubstantially the same as OD_(E), OD_(DEPLOY) can be smaller thanOD_(E), or OD_(DEPLOY) can be larger than OD_(E).

In another exemplary method, as shown in FIG. 16, a new pattern isderived empirically from a base pattern by observing actual radialcompression on a stent scaffold. A first stent scaffold is formed 92 byapplying a base pattern to a precursor tube having an outer diameterOD_(P) so that the first stent scaffold also has an outer diameterOD_(P). The base pattern and OD_(P) are such that the first stentscaffold is capable of deploying to an outer diameter OD_(DEPLOY).Control points on the first stent scaffold are marked, such as withindelible ink. Next, the first stent scaffold is radially compressed 94to a reduced outer diameter OD_(PR). The new position of the controlpoints are determined, such as by visual inspection using an opticalcomparator or a video system. The new position of the control points areused to design 96 a new pattern that corresponds to the actual shape ofthe first stent scaffold after radially compression to OD_(PR). A secondstent scaffold is formed 98 by applying the new pattern on a precursortube having the reduced outer diameter OD_(PR). The second stentscaffold can then be crimped 100 to OD_(CRIMP) onto a delivery balloonand subsequently deployed 102 to OD_(DEPLOY) by inflating the balloon.In FIG. 16, OD_(E) and OD_(DEPLOY) are not substantially the same. Itwill be appreciated that, depending on the anatomical lumen beingtreated, OD_(DEPLOY) can be substantially the same as OD_(P),OD_(DEPLOY) can be smaller than OD_(P), or OD_(DEPLOY) can be largerthan OD_(P).

The new pattern 700 of FIG. 9 will now be described in greater detail.As previously indicated, the new pattern 700 was derived from the basepattern 40 of FIG. 5 according to the method of FIG. 8, and was shown tohave improved toughness or fracture resistance during crimping. It iscontemplated that the new pattern 700 and other patterns can also bederived according to the method described above in connection with FIGS.14A-14C, 15 and 16.

The pattern 700 includes various structural elements 702 oriented indifferent directions and gaps 703 between the structural elements. Eachgap 703 and the structural elements 702 immediately surrounding the gap703 defines a W-shaped closed cell 736. At the proximal and distal endsof the stent, a strut 706 includes depressions, blind holes, or throughholes adapted to hold a radiopaque marker that allows the position ofthe stent inside of a patient to be determined. All the cells 736 havesubstantially the same size and shape.

The pattern 700 is shown in a planar or flat state, although the patternis actually in tubular form when cut onto a precursor tube. The bottomedge 708 of the pattern actually meets with and is connected to the topedge 710 of the pattern so as to form the tubular body of the stentscaffold. In this way, the pattern 700 forms sinusoidal hoops or rings712 that include a group of struts arranged circumferentially. The rings712 include a series of crests and troughs that alternate with eachother. The sinusoidal variation of the rings 712 occurs primarily in theaxial direction, not in the radial direction so that all points on theouter surface of each ring 712 are at substantially the same radialdistance away from the central axis of the stent.

The rings 712 are connected to each other by substantially linear links734. The rings 712 are capable of being collapsed to a smaller diameterduring crimping and expanded to their original diameter or to a largerdiameter during deployment. In other embodiments, the pattern may have adifferent number of rings 712. The number of rings 712 may varydepending on the desired axial length of the stent.

Referring again to FIG. 9, the rings 712 include substantially linearstruts 730 and curved bending elements 732. The struts 730 are connectedto each other by the bending elements 732. The bending elements 732 areadapted to flex, which allows the rings 712 to be radially compressedand radially expanded.

It is to be understood that the pattern 700 corresponds to a stentscaffold which has not been crimped or otherwise deformed from itsoriginal outer diameter, wherein the outer diameter is that of theprecursor tube used to make the stent scaffold. The angles describedbelow for the pattern 700 also apply to the stent scaffold in thenon-deformed state before any crimping and before any expansion by adelivery balloon.

The struts 730 are oriented at an interior angle θ relative to eachother. The interior angle θ is no greater than 100 degrees. Preferably,the interior angle θ is from about 75 degrees to about 95 degrees, andmore narrowly from about 80 degrees to about 95 degrees. By comparison,the interior angle φ between struts of the base pattern 40 is greaterthan 100 degrees, and is from about 115 degrees to about 130 degrees. Itwill be appreciated that the struts 730 of the new pattern 700 of FIG. 9are oriented closer to the axial direction (horizontal arrow 43) thanthe struts of the base pattern 40 of FIG. 5, which can cause a change instrength of the individual struts and a change in hoop strength of therings formed by the struts. As previously indicated, the angles and theorientation of the struts affects mechanical properties due to theradial expansion of the extruded tube during the blow molding processand the resulting molecular orientation of polymer chains. With a largeamount of radial expansion during blow molding, molecular polymer chainorientation could be expected to be more circumferential than axial, inwhich case, structural elements of the stent scaffold which are orientedcloser to the axial direction (horizontal arrow 43) could be expected tobe less rigid than structural elements oriented closer to thecircumferential direction (vertical arrow 41). On the other hand, with asmall amount of radial expansion during blow molding, molecular polymerchain orientation could be expected to be more axial thancircumferential, in which case, structural elements of the stentscaffold which are oriented closer to the axial direction (horizontalarrow 43) could be expected to be more rigid than structural elementsoriented closer to the circumferential direction (vertical arrow 41).Any change in axial elongation during the blow molding process can alsoaffect molecular polymer chain orientation as well as rigidity andflexibility of stent scaffold structural elements.

Referring again to FIG. 9, the struts 730, bending elements 732, andlinks 734 define the plurality of W-shaped closed cells 736. TheW-shapes appear rotated 90 degrees. Each of the W-shaped cells 736 isimmediately surrounded by six other W-shaped cells 736, meaning that theperimeter of each W-shaped cell 736 merges with a portion of theperimeter of six other W-shaped cells 736. Stated another way, eachW-shaped cell 736 abuts or touches six other W-shaped cells 736. Thereare exactly three W-shaped closed cells 736 that span thecircumferential dimension of the pattern. Also, each pair of adjacentrings 713 forms exactly three W-shaped closed cells.

The perimeter of each W-shaped cell 736 includes eight of the struts730, two of the links 734, and ten of the bending elements 732. Four ofthe eight struts form a proximal side of the cell perimeter and theother four struts form a distal side of the cell perimeter. The opposingstruts on the proximal and distal sides are substantially parallel toeach other.

A stent according to the present invention can comprise a stent scaffoldfabricated as described above using a base pattern or a new patternderived from a base pattern. The stent scaffold can be covered with adrug coating and/or the stent scaffold itself can be impregnated orinfused with a drug. The drug elutes from the stent scaffold afterdeployment.

The drug carried within and/or on the stent scaffold can be any suitabletherapeutic agent known in the art of stents and other implantabledevices. The therapeutic agent can be in a substantially pure form. Thetherapeutic agent can be mixed, dispersed, dissolved, encapsulated orotherwise carried in a polymer.

Therapeutic agents include without limitation an anti-restenosis agent,an antiproliferative agent, an anti-inflammatory agent, anantineoplastic, an antimitotic, an antiplatelet, an anticoagulant, anantifibrin, an antithrombin, a cytostatic agent, an antibiotic, ananti-enzymatic agent, an angiogenic agent, a cyto-protective agent, acardioprotective agent, a proliferative agent, an ABC A1 agonist, anantioxidant, a cholesterol-lowering agent, aspirin, anangiotensin-converting enzyme, a beta blocker, a calcium channelblocker, nitroglycerin, a long-acting nitrate, a glycoprotein IIb-IIIainhibitor or any combination thereof.

Examples of antiproliferative agents include, without limitation,actinomycins, taxol, docetaxel, paclitaxel, rapamycin,40-O-(3-hydroxy)propyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, or 40-O-tetrazole-rapamycin,40-epi-(N1-tetrazolyl)-rapamycin, ABT-578, zotarolimus, everolimus,biolimus, novolimus, myolimus, deforolimus, temsirolimus, perfenidoneand derivatives, analogs, prodrugs, co-drugs and combinations of any ofthe foregoing.

While several particular forms of the invention have been illustratedand described, it will also be apparent that various modifications canbe made without departing from the scope of the invention. For example,it will be appreciated that the method of deriving a new pattern from abase pattern can be performed with a base pattern other than the basepattern of FIG. 5. It is also contemplated that various combinations orsubcombinations of the specific features and aspects of the disclosedembodiments can be combined with or substituted for one another in orderto form varying modes of the invention. Accordingly, it is not intendedthat the invention be limited, except as by the appended claims.

What is claimed is:
 1. A method of manufacturing a stent, the methodcomprising: determining a shape of a first stent scaffold radiallycompressed to a reduced outer diameter, the stent scaffold capable ofbeing deployed to an expanded outer diameter; determining a pattern fromthe determined shape; and forming a second stent scaffold by applyingthe determined pattern to a precursor tube having the reduced outerdiameter, the second stent scaffold capable of being deployed to theexpanded outer diameter.
 2. The method of claim 1, wherein determiningthe shape of the first stent scaffold comprises constructing a numericalmodel of the first stent scaffold and simulating radial compression ofthe numerical model to the reduced outer diameter.
 3. The method ofclaim 2, wherein determining the pattern comprises selecting controlpoints on the numerical model, determining new positions of the controlpoints after the simulating of radial compression, and using the newpositions to design the pattern.
 4. The method of claim 1, whereindetermining the shape of the first stent scaffold comprises radiallycompressing the first stent scaffold.
 5. The method of claim 4, whereindetermining the pattern comprises identifying control points on thefirst stent scaffold, determining new positions of the control pointsafter the first stent scaffold is radially compressed, and using the newpositions to design the pattern.
 6. The method of claim 1, wherein thereduced outer diameter is about 3.0 mm, and the second stent scaffold iscapable of being crimped to an outer diameter of about 1.3 mm withoutsubstantial damage and capable of being deployed up to an outer diameterof about 3.8 mm.
 7. The method of claim 6, wherein the precursor tube ismade of PLLA and the determined pattern includes a plurality of W-shapedclosed cells.
 8. The method of claim 7, wherein the W-shape closed cellsare bounded by struts that are substantially linear, the struts orientedin such a way to form interior angles from about 80 degrees to about 95degrees between every two adjacent struts.
 9. The method of claim 7,wherein the precursor tube is fabricated from an extruded tube made ofPLLA, the extruded tube being radially expanded to an outer diameter ofabout 3.0 mm.
 10. A method of manufacturing a stent, the methodcomprising: providing a precursor tube made of PLLA; forming a stentscaffold by applying a pattern of struts on the precursor tube, thepattern comprising a plurality of W-shaped closed cells, each W-shapeclosed cell bounded by struts that are substantially linear, the strutsoriented in such a way to form interior angles from about 80 degrees toabout 95 degrees between every two adjacent struts.
 11. The method ofclaim 10, wherein the precursor tube is fabricated from an extruded tubemade of PLLA, the extruded tube being radially expanded to an outerdiameter of about 3.0 mm.
 12. The method of claim 11, wherein the stentscaffold is capable of being crimped to an outer diameter of about 1.3mm without substantial damage and capable of being deployed up to anouter diameter of about 3.8 mm.
 13. The method of claim 10, wherein thestruts from a plurality of rings, each pair of adjacent rings connectedto each other by links that are substantially linear, and exactly threeW-shaped closed cells are enclosed within each pair of adjacent rings.14. A polymeric stent comprising: a stent scaffold made of PLLA, thestent scaffold comprising a plurality of struts forming a plurality ofrings, each pair of adjacent rings connected to each other by links thatare substantially linear, there being exactly three W-shaped closedcells enclosed within each pair of adjacent rings, the struts beingsubstantially linear and oriented in such a way to form interior anglesfrom about 80 degrees to about 95 degrees between every two adjacentstruts.
 15. The polymeric stent of claim 14, wherein the stent scaffoldis cut from a precursor tube having an outer diameter of about 3.0 mm,the precursor tube fabricated from an extruded tube made of PLLA, theextruded tube being radially expanded to an outer diameter of about 3.0mm.
 16. The polymeric stent of claim 14, wherein the stent scaffold hasan outer diameter of about 3.0 mm.
 17. The polymeric stent of claim 16,wherein the stent scaffold is capable of being crimped to an outerdiameter of about 1.3 mm without substantial damage and capable of beingdeployed up to an outer diameter of about 3.8 mm.
 18. The polymericstent of claim 16, wherein the stent scaffold is formed from a patternof struts derived from an other stent scaffold radially compressed to anouter diameter of about 3.0 mm.
 19. The polymeric stent of claim 18,wherein the stent scaffold and the other stent scaffold are both capableof being deployed up to an outer diameter of about 3.8 mm.